Clinical Trials Using Modified Vaccinia Virus Ankara Vaccine Expressing p53

Clinical trials are research studies that involve people. The clinical trials on this list are studying Modified Vaccinia Virus Ankara Vaccine Expressing p53. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • P53MVA and Pembrolizumab in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    This phase II trial studies how well modified vaccinia virus ankara vaccine expressing p53 (p53MVA) and pembrolizumab work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving p53MVA and pembrolizumab together may work better in treating patients with ovarian, primary peritoneal, or fallopian tube cancer.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California